These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28322836)

  • 21. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The overexpression of KIT proto-oncogene in acute leukemic cells is not necessarily caused by the gene mutation.
    Szatkowski D; Hellmann A
    Acta Haematol; 2015; 133(1):116-23. PubMed ID: 25247397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia.
    Sharawat SK; Gupta R; Raina V; Kumar L; Sharma A; Iqbal S; Bakhshi R; Vishnubhatla S; Bakhshi S
    Cytometry B Clin Cytom; 2013; 84(6):390-7. PubMed ID: 23740774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.
    Goemans BF; Zwaan CM; Cloos J; de Lange D; Loonen AH; Reinhardt D; Hählen K; Gibson BE; Creutzig U; Kaspers GJ
    Leuk Res; 2010 Oct; 34(10):1302-7. PubMed ID: 20435347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
    Beghini A; Cairoli R; Morra E; Larizza L
    Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia.
    Eriksson A; Kalushkova A; Jarvius M; Hilhorst R; Rickardson L; Kultima HG; de Wijn R; Hovestad L; Fryknäs M; Öberg F; Larsson R; Parrow V; Höglund M
    Biochem Pharmacol; 2014 Jan; 87(2):284-91. PubMed ID: 24200998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
    Yang Y; Huang Q; Lu Y; Li X; Huang S
    J Cell Biochem; 2012 Apr; 113(4):1314-22. PubMed ID: 22109829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High receptor tyrosine kinase (FLT3, KIT) transcript versus anti-apoptotic (BCL2) transcript ratio independently predicts inferior outcome in pediatric acute myeloid leukemia.
    Sharawat SK; Bakhshi R; Vishnubhatla S; Bakhshi S
    Blood Cells Mol Dis; 2015 Jan; 54(1):56-64. PubMed ID: 25216797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling.
    Heo SK; Noh EK; Seo HJ; Lee YJ; Koh S; Min YJ; Choi Y; Jo JC
    PLoS One; 2022; 17(5):e0265958. PubMed ID: 35503759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Clin Cancer Res; 2001 Dec; 7(12):3884-93. PubMed ID: 11751479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro effect of STI571 on expression of c-kit in bone marrow cells from patients with acute non-lymphocytic leukemia].
    Tan Tai LF; Yi ZS; Feng R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):256-8. PubMed ID: 12844407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
    Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
    Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mast cell growth factor, a ligand for the receptor encoded by c-kit, affects the growth in culture of the blast cells of acute myeloblastic leukemia.
    Wang C; Koistinen P; Yang GS; Williams DE; Lyman SD; Minden MD; McCulloch EA
    Leukemia; 1991 Jun; 5(6):493-9. PubMed ID: 1711640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radotinib-induced lentiginosis: a report of an adverse cutaneous reaction associated with a tyrosine kinase inhibitor.
    Won KH; Jo SY; Lee YJ; Chang SE
    Clin Exp Dermatol; 2016 Mar; 41(2):162-5. PubMed ID: 26190691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
    Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-137 downregulates c-kit expression in acute myeloid leukemia.
    Hu Y; Dong X; Chu G; Lai G; Zhang B; Wang L; Zhao Y
    Leuk Res; 2017 Jun; 57():72-77. PubMed ID: 28314168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].
    Goryainova NV
    Lik Sprava; 2014 Dec; (12):10-8. PubMed ID: 26638462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.
    Moshaver B; van Rhenen A; Kelder A; van der Pol M; Terwijn M; Bachas C; Westra AH; Ossenkoppele GJ; Zweegman S; Schuurhuis GJ
    Stem Cells; 2008 Dec; 26(12):3059-67. PubMed ID: 19096043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
    Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
    BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.